PHAT Initiates Coverage On Leerink Partners -- Rating Set to Market Perform

gurufocus.com · 2026-09-09

Phathom Pharmaceuticals: Analyst Coverage Initiation and Valuation Insights On October 17, 2023, Phathom Pharmaceuticals (PHAT) received a new analyst rating

TickrTrends take: Leerink Partners has initiated coverage of PHAT with a Market Perform rating, which represents a neutral stance on the stock's near-term direction. Given that TickrTrends' current valuation assessment for PHAT remains awaiting full valuation, this analyst initiation provides additional perspective on how the market may be pricing the Healthcare company relative to its fundamentals. Valuation-focused investors should monitor whether subsequent analyst coverage and price targets help establish clearer valuation benchmarks for PHAT as more research accumulates.

Read the full story at gurufocus.com →